Eyepoint Pharms Drug Patent Portfolio
Eyepoint Pharms owns 1 orange book drug protected by 7 US patents Given below is the list of Eyepoint Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11097061 | Systems, kits and methods for loading and delivering a small volume dose from a syringe | 23 Jun, 2039 | Active |
| US10022502 | Dose guides for injection syringe | 22 Jun, 2034 | Active |
| US10028965 | Use of sustained release dexamethasone in post-cataract surgery inflammation | 23 May, 2034 | Active |
| US10159683 | Use of sustained release dexamethasone in post-cataract surgery inflammation | 23 May, 2034 | Active |
| US10799642 | Dose guides for injection syringe | 11 May, 2032 | Active |
| US6960346 | Vehicles for delivery of biologically active substances | 03 Jul, 2023 | Expired |
| US7560120 | Vehicles for delivery of biologically active substances | 05 Sep, 2022 | Expired |
Latest Legal Activities on Eyepoint Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Eyepoint Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 27 Mar, 2024 | US10799642 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 Jun, 2022 | US10159683 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Jan, 2022 | US10028965 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 05 Jan, 2022 | US10022502 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 24 Aug, 2021 | US11097061 |
|
Recordation of Patent Grant Mailed
Critical
| 24 Aug, 2021 | US11097061 |
|
Email Notification
Critical
| 05 Aug, 2021 | US11097061 |
|
Issue Notification Mailed
Critical
| 04 Aug, 2021 | US11097061 |
|
Application Is Considered Ready for Issue
Critical
| 22 Jul, 2021 | US11097061 |
| Dispatch to FDC | 22 Jul, 2021 | US11097061 |
|
Issue Fee Payment Received
Critical
| 21 Jul, 2021 | US11097061 |
|
Issue Fee Payment Verified
Critical
| 21 Jul, 2021 | US11097061 |
|
Electronic Review
Critical
| 23 Apr, 2021 | US11097061 |
|
Email Notification
Critical
| 23 Apr, 2021 | US11097061 |
|
Mail Notice of Allowance
Critical
| 23 Apr, 2021 | US11097061 |
Eyepoint Pharms's Family Patents
Eyepoint Pharms drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 37.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Eyepoint Pharms Drug List
Given below is the complete list of Eyepoint Pharms's drugs and the patents protecting them.
1. Dexycu Kit
Dexycu Kit is protected by 7 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11097061 | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
23 Jun, 2039
(14 years from now)
| Active |
| US10022502 | Dose guides for injection syringe |
22 Jun, 2034
(9 years from now)
| Active |
| US10028965 | Use of sustained release dexamethasone in post-cataract surgery inflammation |
23 May, 2034
(9 years from now)
| Active |
| US10159683 | Use of sustained release dexamethasone in post-cataract surgery inflammation |
23 May, 2034
(9 years from now)
| Active |
| US10799642 | Dose guides for injection syringe |
11 May, 2032
(7 years from now)
| Active |
| US6960346 | Vehicles for delivery of biologically active substances |
03 Jul, 2023
(1 year, 10 months ago)
| Expired |
| US7560120 | Vehicles for delivery of biologically active substances |
05 Sep, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dexycu Kit's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List